Fore Bio
Fore Biotherapeutics
Israel · Founded 2011 · $170.0M raised
- Founded
- 2011
- Business Model
- B2B
- Website
- fore.bio
- Total Funding
- $170.0M
- Last Round
- $75.0M Series DMay 2025
- Rounds
- 4
About
Fore Biotherapeutics is a precision oncology company developing cancer therapies guided by proprietary functional genomics. Its lead program, plixorafenib (FORE-8394), is being evaluated in the FORTE Trial for patients with BRAF-altered solid tumors. The company is committed to patient-first, hypothesis-driven science to address difficult-to-treat cancers.
Summary
Fore Bio is a Biotech company based in Israel, founded in 2011. It has raised $170.0M in total across 4 rounds, most recently a $75.0M Series D round in May 2025. Investors include OrbiMed and Medicxi.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
May 2025
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...